A detailed history of Virtus ETF Advisers LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 1,962 shares of CRNX stock, worth $107,360. This represents 0.05% of its overall portfolio holdings.

Number of Shares
1,962
Previous 1,931 1.61%
Holding current value
$107,360
Previous $86,000 16.28%
% of portfolio
0.05%
Previous 0.04%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$43.83 - $54.98 $1,358 - $1,704
31 Added 1.61%
1,962 $100,000
Q2 2024

Aug 14, 2024

SELL
$42.12 - $51.91 $23,081 - $28,446
-548 Reduced 22.11%
1,931 $86,000
Q1 2024

May 15, 2024

SELL
$34.76 - $46.81 $6,083 - $8,191
-175 Reduced 6.59%
2,479 $116,000
Q4 2023

Feb 15, 2024

SELL
$25.62 - $37.07 $56,235 - $81,368
-2,195 Reduced 45.27%
2,654 $94,000
Q3 2023

Nov 07, 2023

SELL
$15.97 - $30.59 $7,729 - $14,805
-484 Reduced 9.08%
4,849 $144,000
Q2 2023

Aug 14, 2023

SELL
$15.73 - $23.6 $13,873 - $20,815
-882 Reduced 14.19%
5,333 $96,000
Q1 2023

May 15, 2023

SELL
$15.31 - $21.1 $36,483 - $50,281
-2,383 Reduced 27.72%
6,215 $99,000
Q4 2022

Feb 14, 2023

BUY
$15.49 - $19.05 $36,711 - $45,148
2,370 Added 38.05%
8,598 $157,000
Q3 2022

Nov 14, 2022

BUY
$18.11 - $22.37 $869 - $1,073
48 Added 0.78%
6,228 $122,000
Q2 2022

Aug 12, 2022

SELL
$16.49 - $27.64 $2,737 - $4,588
-166 Reduced 2.62%
6,180 $115,000
Q1 2022

May 16, 2022

SELL
$17.15 - $28.31 $6,516 - $10,757
-380 Reduced 5.65%
6,346 $139,000
Q4 2021

Feb 14, 2022

SELL
$19.35 - $28.41 $87,055 - $127,816
-4,499 Reduced 40.08%
6,726 $191,000
Q3 2021

Nov 15, 2021

SELL
$16.88 - $25.23 $9,874 - $14,759
-585 Reduced 4.95%
11,225 $236,000
Q2 2021

Aug 10, 2021

SELL
$15.9 - $21.15 $160,144 - $213,022
-10,072 Reduced 46.03%
11,810 $223,000
Q1 2021

May 17, 2021

BUY
$13.3 - $17.55 $5,253 - $6,932
395 Added 1.84%
21,882 $334,000
Q4 2020

Feb 12, 2021

BUY
$12.08 - $17.46 $25,561 - $36,945
2,116 Added 10.92%
21,487 $303,000
Q3 2020

Nov 13, 2020

SELL
$13.62 - $17.66 $36,161 - $46,887
-2,655 Reduced 12.05%
19,371 $304,000
Q2 2020

Aug 05, 2020

BUY
$13.04 - $23.23 $287,219 - $511,663
22,026 New
22,026 $386,000
Q2 2019

Aug 13, 2019

SELL
$21.48 - $27.71 $170,422 - $219,851
-7,934 Closed
0 $0
Q1 2019

May 14, 2019

SELL
$21.07 - $29.31 $23,177 - $32,241
-1,100 Reduced 12.18%
7,934 $181,000
Q4 2018

Feb 05, 2019

BUY
$22.4 - $35.39 $202,361 - $319,713
9,034 New
9,034 $271,000

Others Institutions Holding CRNX

About Crinetics Pharmaceuticals, Inc.


  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $2.94B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.